- Home
- ANAB vs CODI Comparison
ANAB vs CODI Comparison
Compare ANAB & CODI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CODI
- Stock Information
- Founded
- ANAB 2005
- CODI 2005
- Country
- ANAB United States
- CODI United States
- Employees
- ANAB N/A
- CODI N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CODI Home Furnishings
- Sector
- ANAB Health Care
- CODI Consumer Discretionary
- Exchange
- ANAB Nasdaq
- CODI Nasdaq
- Market Cap
- ANAB 621.1M
- CODI 565.8M
- IPO Year
- ANAB 2017
- CODI 2006
- Fundamental
- Price
- ANAB $23.17
- CODI $6.39
- Analyst Decision
- ANAB Buy
- CODI Buy
- Analyst Count
- ANAB 10
- CODI 2
- Target Price
- ANAB $44.25
- CODI $26.00
- AVG Volume (30 Days)
- ANAB 775.6K
- CODI 1.9M
- Earning Date
- ANAB 08-04-2025
- CODI 07-30-2025
- Dividend Yield
- ANAB N/A
- CODI 15.67%
- EPS Growth
- ANAB N/A
- CODI N/A
- EPS
- ANAB N/A
- CODI N/A
- Revenue
- ANAB $111,872,000.00
- CODI $2,198,233,000.00
- Revenue This Year
- ANAB N/A
- CODI $8.09
- Revenue Next Year
- ANAB $24.39
- CODI $7.62
- P/E Ratio
- ANAB N/A
- CODI N/A
- Revenue Growth
- ANAB 387.20
- CODI 11.87
- 52 Week Low
- ANAB $12.21
- CODI $6.00
- 52 Week High
- ANAB $41.31
- CODI $24.59
- Technical
- Relative Strength Index (RSI)
- ANAB 56.01
- CODI 31.99
- Support Level
- ANAB $22.46
- CODI $6.01
- Resistance Level
- ANAB $24.17
- CODI $6.49
- Average True Range (ATR)
- ANAB 1.72
- CODI 0.40
- MACD
- ANAB -0.01
- CODI 0.29
- Stochastic Oscillator
- ANAB 73.23
- CODI 25.16
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CODI D/B/A Compass Diversified Holdings Shares of Beneficial Interest
Compass Diversified Holdings is a diversified business conglomerate based in the United States having two groups: branded consumer business and industrial business. Branded consumer businesses are characterized as those businesses that capitalize on a valuable brand name in their respective market sector. It includes 5.11, Ergobaby, Liberty Safe, and Velocity Outdoor. Industrial businesses are characterized as those businesses that focus on manufacturing and selling particular products and industrial services within a specific market sector. The company has operations in the United States, Canada, Europe, Asia Pacific, and other International areas.